title: Modeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS).
abstract: Individuals with inflammatory bowel disease (IBD), such as Crohn's disease (CD) or ulcerative colitis (UC) are at increased risk of developing colorectal cancer (CRC) over healthy individuals. This risk is proportional to the duration and extent of disease, with a cumulative incidence as high as 30% in individuals with longstanding UC with widespread colonic involvement. Colonic dysplasia in IBD and colitis associated cancer (CAC) are believed to develop as a result of repeated cycles of epithelial cell injury and repair while these cells are bathed in a chronic inflammatory cytokine milieu. While spontaneous and colitis-associated cancers share the quality of being adenocarcinomas, the sequence of underlying molecular events is believed to be different. This distinction argues the need for specific animal models of CAC. Several mouse models currently exist for the study of CAC. Dextran sulfate sodium (DSS), an agent with direct toxic effects on the colonic epithelium, can be administered in drinking water to mice in multiple cycles to create a chronic inflammatory state. With sufficient duration, some of these mice will develop tumors. Tumor development is hastened in this model if administered in a pro-carcinogenic setting. These include mice with genetic mutations in tumorigenesis pathways (APC, p53, Msh2), as well as mice pre-treated with genotoxic agents (azoxymethane [AOM], 1,2-dimethylhydrazine [DMH]). The combination of DSS with AOM as a model for colitis associated cancer has gained popularity for its reproducibility, potency, low price, and ease of use. Though they have a shared mechanism, AOM has been found to be more potent and stable in solution than DMH. While tumor development in other models generally requires several months, mice injected with AOM and subsequently treated with DSS develop adequate tumors in as little as 7-10 weeks. Finally, AOM and DSS can be administered to mice of any genetic background (knock out, transgenic, etc.) without cross-breeding to a specific tumorigenic strain. Here, we demonstrate a protocol for inflammation-driven colonic tumorigenesis in mice utilizing a single injection of AOM followed by three seven-day cycles of DSS over a 10 week period. This model induces tumors with histological and molecular changes closely resembling those occurring in human CAC and provides a highly valuable model for the study of oncogenesis and chemoprevention in this disease.
authors.affiliation: Division of Gastroenterology, Washington University School of Medicine, USA.
authors.forename: Ameet I
authors.initials: AI
authors.lastname: Thaker
authors.forename: Anisa
authors.initials: A
authors.lastname: Shaker
authors.forename: M Suprada
authors.initials: MS
authors.lastname: Rao
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Ciorba
mesh_terms: D000818:Animals; D001397:Azoxymethane; D003092:Colitis / Q000139:chemically induced* / Q000473:pathology*; D003110:Colonic Neoplasms / Q000139:chemically induced* / Q000473:pathology*; D016264:Dextran Sulfate; D004195:Disease Models, Animal; D005260:Female; D008297:Male; D051379:Mice
chemical_list: D016264:Dextran Sulfate; D001397:Azoxymethane